PRMT1 and cancer: Later, a number of chemically symmetrical diamidine compounds as PRMT1 inhibitors with activities against cancer cells were reported, including stilbamidine (Spannhoff et al., 2007) and furamidine (DB75) (Yan et al., 2014).